Hu-rhEGF-rP64k/Mont

Hu-rhEGF-rP64k/Mont Uses, Dosage, Side Effects, Food Interaction and all others data.

Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).

Table Of contents

• Hu-rhEGF-rP64k/Mont
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Hu-rhEGF-rP64k/Mont
Generic	Hu-rhEGF-rP64k/Mont
Type
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Hu-rhEGF-rP64k/Mont is a vaccine used to prevent recurrence of certain lung cancers in patients who have already received cyclophosphamide.

Hu-rhEGF-rP64k/Mont is also used to associated treatment for these conditions: Advanced Non Small Cell Lung Cancer

Innovators Monograph

You find simplified version here Hu-rhEGF-rP64k/Mont